NASDAQ:MDGL Madrigal Pharmaceuticals (MDGL) Stock Forecast, Price & News $264.62 +4.68 (+1.80%) (As of 01:21 PM ET) Add Compare Share Share Today's Range$258.03▼$267.1650-Day Range$234.08▼$312.0052-Week Range$57.21▼$322.67Volume76,069 shsAverage Volume383,604 shsMarket Capitalization$4.84 billionP/E RatioN/ADividend YieldN/APrice Target$312.36 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Madrigal Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside18.2% Upside$312.36 Price TargetShort InterestHealthy9.01% of Float Sold ShortDividend StrengthN/ASustainability-0.92Upright™ Environmental ScoreNews Sentiment0.46Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($18.65) to ($8.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.29 out of 5 starsMedical Sector293rd out of 980 stocksPharmaceutical Preparations Industry134th out of 485 stocks 2.4 Analyst's Opinion Consensus RatingMadrigal Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $312.36, Madrigal Pharmaceuticals has a forecasted upside of 18.2% from its current price of $264.25.Amount of Analyst CoverageMadrigal Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted9.01% of the float of Madrigal Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMadrigal Pharmaceuticals has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Madrigal Pharmaceuticals has recently decreased by 8.70%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMadrigal Pharmaceuticals does not currently pay a dividend.Dividend GrowthMadrigal Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMadrigal Pharmaceuticals has received a 73.28% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Madrigal Pharmaceuticals is -0.92. Previous Next 2.5 News and Social Media Coverage News SentimentMadrigal Pharmaceuticals has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Madrigal Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 7 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows9 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Madrigal Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders24.49% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.98% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($18.65) to ($8.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Madrigal Pharmaceuticals is -14.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Madrigal Pharmaceuticals is -14.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMadrigal Pharmaceuticals has a P/B Ratio of 22.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Madrigal Pharmaceuticals (NASDAQ:MDGL) StockMadrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.Read More Receive MDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MDGL Stock News HeadlinesJune 4, 2023 | finance.yahoo.comMDGL Jun 2023 257.500 putMay 30, 2023 | seekingalpha.comMadrigal: Setting The Pace In The NASH Market (Rating Upgrade)June 5, 2023 | Edge On The Street (Ad)Investor Alert: EV Initiatives Create Unsustainable Demand For LithiumThe soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.May 29, 2023 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded to "Hold" at StockNews.comMay 26, 2023 | fool.comMadrigal Pharmaceuticals (NASDAQ: MDGL)May 25, 2023 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Trading 4.1% Higher May 23, 2023 | benzinga.comLooking At Madrigal Pharmaceuticals's Recent Unusual Options ActivityMay 22, 2023 | americanbankingnews.comStockNews.com Downgrades Madrigal Pharmaceuticals (NASDAQ:MDGL) to SellJune 5, 2023 | Edge On The Street (Ad)New "Mined in America" Lithium Opportunities?The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.May 21, 2023 | americanbankingnews.comBrokerages Set Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Target Price at $312.36May 18, 2023 | americanbankingnews.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Short Interest Down 6.8% in AprilMay 17, 2023 | msn.comUnusual Call Option Trade in Madrigal Pharmaceuticals (MDGL) Worth $2,637.87KMay 16, 2023 | msn.comOppenheimer Maintains Madrigal Pharmaceuticals (MDGL) Outperform RecommendationMay 16, 2023 | msn.comAnalyst Expectations for Madrigal Pharmaceuticals's FutureMay 16, 2023 | finance.yahoo.comWhy These 3 Nasdaq Stocks Buckled TodayMay 16, 2023 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) PT Raised to $350.00 at OppenheimerMay 15, 2023 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Raised to Hold at StockNews.comMay 11, 2023 | finance.yahoo.comMadrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences ConferenceMay 11, 2023 | finance.yahoo.comTop Small-Cap Stocks for May 2023May 11, 2023 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 11.4%May 10, 2023 | msn.comCanaccord Genuity Reiterates Madrigal Pharmaceuticals (MDGL) Buy RecommendationMay 9, 2023 | markets.businessinsider.comJMP Securities Reaffirms Their Buy Rating on Madrigal Pharmaceuticals (MDGL)May 9, 2023 | finance.yahoo.comWhy Madrigal Pharmaceuticals Stock Is Slumping TodayMay 9, 2023 | finanznachrichten.deMadrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial ResultsMay 9, 2023 | finance.yahoo.comMadrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial ResultsMay 8, 2023 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)May 8, 2023 | americanbankingnews.comReviewing Biohaven (NYSE:BHVN) and Madrigal Pharmaceuticals (NASDAQ:MDGL)See More Headlines MDGL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDGL Company Calendar Last Earnings5/09/2023Today6/05/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:MDGL CUSIP87162T20 CIK1157601 Webwww.madrigalpharma.com Phone(267) 824-2827Fax781-274-8228Employees71Year Founded2011Price Target and Rating Average Stock Price Forecast$312.36 High Stock Price Forecast$390.00 Low Stock Price Forecast$194.00 Forecasted Upside/Downside+20.2%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($18.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-295,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-285.00% Return on Assets-117.65% Debt Debt-to-Equity Ratio0.56 Current Ratio3.37 Quick Ratio3.37 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.54 per share Price / Book22.53Miscellaneous Outstanding Shares18,290,000Free Float13,810,000Market Cap$4.75 billion OptionableOptionable Beta-0.71 Social Links Key ExecutivesPaul A. FriedmanChairman, President & Chief Executive OfficerAlex G. HowarthChief Financial OfficerEdward ChiangSVP-Clinical & Technical OperationsRebecca A. TaubDirector & Chief Medical OfficerStephen DodgeSenior Vice President-Global Medical AffairsKey CompetitorsAlkermesNASDAQ:ALKSIonis PharmaceuticalsNASDAQ:IONSAmicus TherapeuticsNASDAQ:FOLDImmunoGenNASDAQ:IMGNGeronNASDAQ:GERNView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 297 shares on 5/26/2023Ownership: 0.015%Legato Capital Management LLCBought 2,015 shares on 5/25/2023Ownership: 0.011%Verity Asset Management Inc.Bought 452 shares on 5/24/2023Ownership: 0.008%Capital Impact Advisors LLCBought 438 shares on 5/23/2023Ownership: 0.016%Ameriprise Financial Inc.Sold 120 shares on 5/22/2023Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions MDGL Stock - Frequently Asked Questions Should I buy or sell Madrigal Pharmaceuticals stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDGL shares. View MDGL analyst ratings or view top-rated stocks. What is Madrigal Pharmaceuticals' stock price forecast for 2023? 10 brokerages have issued 12-month price targets for Madrigal Pharmaceuticals' stock. Their MDGL share price forecasts range from $194.00 to $390.00. On average, they expect the company's stock price to reach $312.36 in the next twelve months. This suggests a possible upside of 20.2% from the stock's current price. View analysts price targets for MDGL or view top-rated stocks among Wall Street analysts. How have MDGL shares performed in 2023? Madrigal Pharmaceuticals' stock was trading at $290.25 at the beginning of the year. Since then, MDGL stock has decreased by 10.4% and is now trading at $259.94. View the best growth stocks for 2023 here. When is Madrigal Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our MDGL earnings forecast. How were Madrigal Pharmaceuticals' earnings last quarter? Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced its quarterly earnings results on Tuesday, May, 9th. The biopharmaceutical company reported ($4.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.78) by $0.55. What ETFs hold Madrigal Pharmaceuticals' stock? ETFs with the largest weight of Madrigal Pharmaceuticals (NASDAQ:MDGL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Alger Mid Cap 40 ETF (FRTY), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), iShares U.S. Pharmaceuticals ETF (IHE), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Invesco DWA SmallCap Momentum ETF (DWAS). What other stocks do shareholders of Madrigal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Ayala Pharmaceuticals (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild). What is Madrigal Pharmaceuticals' stock symbol? Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL." Who are Madrigal Pharmaceuticals' major shareholders? Madrigal Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Avoro Capital Advisors LLC (9.11%), BlackRock Inc. (5.21%), Perceptive Advisors LLC (3.56%), State Street Corp (2.84%), Assenagon Asset Management S.A. (2.85%) and FMR LLC (1.44%). Insiders that own company stock include Bay City Capital Llc, Brian Joseph Lynch, Fred B Craves, Remy Sukhija and Richard S Levy. View institutional ownership trends. How do I buy shares of Madrigal Pharmaceuticals? Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Madrigal Pharmaceuticals' stock price today? One share of MDGL stock can currently be purchased for approximately $259.94. How much money does Madrigal Pharmaceuticals make? Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $4.75 billion. The biopharmaceutical company earns $-295,350,000.00 in net income (profit) each year or ($18.10) on an earnings per share basis. How can I contact Madrigal Pharmaceuticals? Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for the company is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (267) 824-2827, via email at ir@madrigalpharma.com, or via fax at 781-274-8228. This page (NASDAQ:MDGL) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.